
Pembrolizumab in Combination with Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
Short Title: EA8231
Enrollment Status: Recruiting
NCT #: NCT06524544
Specialty Area: Oncology
Condition Studied: Urothelial Cancer
Age Groups: Adult; Older Adult
Study Information
Summary / Purpose
The purpose of this study is to compare the usual treatment of chemotherapy to using pembrolizumab plus Sacituzumab govitecan-hziy for patients with urothelial cancer. The combination of pembrolizumab and Sacituzumab govitecan-hziy could shrink your cancer or prevent it from growing.
Who Can Participate
- Adults 18+ years of age
- Confirmed locally advanced or metastatic urothelial cancer
- Must have measurable disease
- Must have had at least 1 line of systemic therapy given
What's Involved
- Random assignment to receive either pembrolizumab plus sacituzumab govitecan, both given intravenously (IV), or standard IV chemotherapy chosen by your doctor
- Standard IV chemotherapy, which may include cisplatin or carboplatin with gemcitabine, docetaxel, or paclitaxel, for participants assigned to that group
- Imaging with computed tomography (CT) scans or magnetic resonance imaging (MRI) scans
- Sample collection for research
- Completing questionnaires about your bladder cancer symptoms, fatigue, and quality of life
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT06524544
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.